COMMUNIQUÉS West-GlobeNewswire

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
07/04/2026
New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency GAITHERSBURG, Md., [...]
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
07/04/2026
Access the Moleculin CEO Corner here HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO [...]
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
07/04/2026
CALGARY, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company” ), a drug [...]
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
07/04/2026
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial [...]
SS Innovations to Host SMRSC 2026 in New Delhi, India from April 9-11, 2026
07/04/2026
Conference to Unite Global Leaders at the Forefront of Surgical Robotic Innovation FORT LAUDERDALE, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq [...]
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
07/04/2026
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
07/04/2026
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president [...]
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
07/04/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the publication of its [...]
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
07/04/2026
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, [...]
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
07/04/2026
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
07/04/2026
ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic
07/04/2026
Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged’ with special proteins SonoNeu is part of a collaborative project, also [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
07/04/2026
COPENHAGEN, Denmark, April 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to [...]
Oculis to Participate in Upcoming Investor Conferences
07/04/2026
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Virbac : Déclaration d'actions et de droits de votes 03/2026
07/04/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Transactions in connection with share buy-back program
07/04/2026
Company announcement no. 9 - 26 07 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Virbac : Declaration of the number of shares and voting rights 03/2026
07/04/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Pharming Group to participate in April investor conferences
07/04/2026
Leiden, the Netherlands, April 7, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month [...]
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
07/04/2026
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma [...]

Pages